Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer.
Angiogenesis plays a central role in the development of metastasis in breast cancer. Recent results of large randomized trials show clinically significant improvements in outcomes with the use of bevacizumab in patients with metastatic breast cancer, leading to approval by European and US regulatory agencies. Several other antiangiogenic strategies are in various stages of development. This review discusses the results of recent clinical trials and novel mechanisms of inhibiting angiogenesis, resistance mechanisms, and toxicities; and raises key challenges that face optimal use and development of antiangiogenic agents in breast cancer.
Ademuyiwa
Foluso O
FO
Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA. fademuyi@iupui.edu
Miller
Kathy D
KD
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000098:blood supply*; D005260:Female; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors